ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-994-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.76 million
Profitability
Miscellaneous
Employees36
Next Earnings Date5/1/2019 (Confirmed)
OptionableOptionable
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) posted its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.08). The biotechnology company had revenue of $2.94 million for the quarter, compared to analyst estimates of $1.81 million. ArQule had a negative return on equity of 30.51% and a negative net margin of 60.09%. View ArQule's Earnings History.
When is ArQule's next earnings date?
What guidance has ArQule issued on next quarter's earnings?
ArQule issued an update on its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of $-0.39--0.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $-0.34. The company issued revenue guidance of $3-5 million, compared to the consensus revenue estimate of $5.6 million.
What price target have analysts set for ARQL?
5 brokers have issued twelve-month price objectives for ArQule's shares. Their predictions range from $7.00 to $9.00. On average, they expect ArQule's share price to reach $7.80 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View Analyst Price Targets for ArQule.
What is the consensus analysts' recommendation for ArQule?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.
Has ArQule been receiving favorable news coverage?
News headlines about ARQL stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ArQule earned a news impact score of 1.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Are investors shorting ArQule?
ArQule saw a decrease in short interest in March. As of March 29th, there was short interest totalling 6,267,569 shares, a decrease of 25.6% from the March 15th total of 8,425,892 shares. Based on an average trading volume of 920,645 shares, the short-interest ratio is currently 6.8 days. Approximately 6.4% of the shares of the stock are short sold. View ArQule's Current Options Chain.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Reata Pharmaceuticals (RETA), Insmed (INSM), Portola Pharmaceuticals (PTLA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), The Medicines (MDCO), Uniqure (QURE) and AnaptysBio (ANAB).
What other stocks do shareholders of ArQule own?
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 58)
- Mr. Peter S. Lawrence J.D., Pres, COO, Gen. Counsel & Sec. (Age 56)
- Dr. Brian Schwartz, Chief Medical Officer & Sr. VP (Age 57)
- Mr. Robert J. Weiskopf, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 68)
- Dr. Marc Schegerin M.D., CFO, Head of Strategy & Treasurer
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $6.5901.
How big of a company is ArQule?
ArQule has a market capitalization of $718.98 million and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.
What is ArQule's official website?
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (NASDAQ ARQL)
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
